Ethanolic Extract of *Nerium indicum* Mill. Decreases Transforming Growth Factor Beta-1 and Vascular Endothelial Growth Factor Expressions in Keloid Fibroblasts

Hernita Taurustya¹, Mae Sri Hartati Wahyuningsih²*, Indwiani Astuti²

¹Department of Pharmacology and Therapy, Faculty of Medicine and Health Sciences, Universitas Bengkulu, Bengkulu, Indonesia; ²Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; *Center for Herbal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

**Abstract**

**BACKGROUND:** Keloid is a benign fibroproliferative dermis tumor characterized by an increase in growth factors which induce fibroblast proliferation, excessive migration, and synthesis of collagen. *Nerium indicum* Mill. extract had been studied as a keloid therapy agent. 5α-oleandrin contained in *N. indicum* has antikeloid activity by inhibiting keloid fibroblast proliferation, fibroblast migration, collagen deposition, and transforming growth factor beta-1 (TGF-β1) synthesis.

**OBJECTIVE:** This study aimed to determine the effect of administration of *N. indicum* extract on TGF-β1 and vascular endothelial growth factor (VEGF) expression in keloid fibroblast.

**METHODS:** This research was a quasi-experimental research with a post-test only control group design. The research subjects were fibroblast cells passage IV-VII isolated from patients' keloid tissue with explant techniques. Keloid fibroblast proliferation, fibroblast migration, collagen deposition, and transforming growth factor beta-1 (TGF-β1) synthesis had been studied as a keloid therapy agent. 5α-oleandrin contained in *N. indicum* has antikeloid activity by inhibiting keloid fibroblast proliferation, fibroblast migration, collagen deposition, and transforming growth factor beta-1 (TGF-β1) synthesis.

**RESULT:** The expression of TGF-β1 in the treatment groups of the extract *N. indicum* (2 µg/ml, 1 µg/ml, and 0.5 µg/ml) was significantly lower than a control group of keloid fibroblasts (p < 0.05), according to increased concentration. VEGF expression in the treatment groups of *N. indicum* extract was lower compared to the control group of keloid fibroblasts. A significant decrease in keloid fibroblast VEGF levels occurred at extract concentrations of 2 µg/ml and 1 µg/ml (p < 0.05).

**CONCLUSION:** *N. indicum* extract could decrease TGF-β1 and VEGF expressions compared to control medium in keloid fibroblast cultures.

**Introduction**

Keloid is a dermal fibroproliferation tumor characterized by excessive accumulation of extracellular matrix (ECM) components such as collagen, fibronectin, elastin, proteoglycans, and growth factors [1]. The occurrence of keloids is due to an imbalance between synthesis and degradation of ECM during the wound healing process [2]. In the pathogenesis of keloids, fibroblasts are the dominant cell and keloid fibroblasts have a greater proliferative ability than normal fibroblasts. Increased proliferation of keloid fibroblasts is influenced by increased growth factors such as transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), fibroblast growth factors, platelet-derived growth factor (PDGF), and cytokines' tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6) [3]. Increased TGF-β1 will accelerate mitogenesis of fibroblasts, stimulating the formation of collagen, elastin, and fibronectin. Furthermore, VEGF induces angiogenesis directly through endothelial cell mitogenesis and lead increases vascular permeability and promotes deposition of extravascular fibrin matrix [4]. Keloid management is currently lacking satisfactory results. For example, keloid excision surgical therapy had a recurrence of 45–100% while non-surgical therapy had various side effects such as skin atrophy, telangiectasias, and pigmentation disorders [5]. Various studies were done using plants/herbs that have the potential as keloid therapy agents and milder side effects. *Nerium indicum* Mill. containing active ingredient Oleandrin has been studied potentially as a keloid therapy agent. Oleandrin cytotoxicity (IC₅₀ 15.6 nM) was greater than doxorubicin (IC₅₀ 26.9 nM) and cisplatin (IC₅₀ 79.8 nM) on M19 cell line (melanoma) [6], [7]. 5α-oleandrin has antikeloid activity by inhibiting keloid fibroblast proliferation, fibroblast migration, collagen deposition, and TGF-β1 synthesis [8]. Ethanolic extract...
N. indicum inhibits proliferation of keloid fibroblasts with IC\textsubscript{50} 0.458 µg/ml, also can inhibit collagen deposit with IC\textsubscript{50} 0.055 µg/ml at 72 h incubation period. In incubation 48 h after administration of ethanol extract of N. indicum 1 µg/ml, there was a significant inhibition of migration compared to the control medium [9]. Therefore, based on the above exposures, this study aimed to determine the molecular mechanism of N. indicum extract activity on the expressions of TGF-β1 and VEGF which play an important role in pathogenesis of keloid tumors.

Materials and Methods

**Keloid fibroblast cultured cell**

This research received approval from the Medical and Health Research Ethics Committee of the Faculty of Medicine, Public Health and Nursing Universitas Gadjah Mada based on the Certificate of Ethical Eligibility number: KE/FK/0485/EC/2018. This research was a quasi-experimental research with post-test only control group design.

Keloid fibroblasts used were a subculture passage IV-VII, obtained from the Laboratory of Health Technology, Dermatology Venereology Division, Faculty of Medicine, Public Health and Nursing Universitas Gadjah Mada. Materials used were N. indicum leaves collected from Sleman-Yogyakarta Special District of Indonesia on May 2018, identified at the laboratory plant systematics, and voucher specimen no: UGM/FA/4533/M/03/02 deposited in the Laboratory of Plant Systematics, Faculty of Pharmacy, Universitas Gadjah Mada. Additional materials included amphotericin B-Fungizone (Gibco\textsuperscript{TM}), Dulbecco's Modified Eagle's Medium Low Glucose (Gibco), dimethyl sulfoxide (DMSO) (Merck), MTT (Sigma), penicillin-streptomycin (Gibco BRL), phosphate buffer saline (Gibco), Povidone-iodine 10% (Gibco), and Trypsin EDTA 0.25% (Gibco).

**Extraction of N. indicum**

About 1 kg of dried powder from N. indicum leaves was macerated by ethanol (70%) (2 L). The mixture was stirred periodically for 24 h. The filtrate was separated by filtration (Buchner funnel), and maceration was repeated 3 times. The filtrates obtained were combined and evaporated in vacuo to dryness.

**Tested concentration preparation**

Ethanol extract of N. indicum as much as 5 mg was dissolved with 100 µL of DMSO to obtain a stock solution concentration of 50,000 µg/ml. The stock solution concentration was made into three serial levels: 0.5 µg/ml, 1 µg/ml, and 2 µg/ml.

**The 24 well plate culture preparation**

Cell suspension was counted based on a number of groups in the study in triplicate. Fibroblast cell culture was harvested, washed, and made into suspension. Cells (3 × 10\textsuperscript{4} cells/well) were seeded into 24 well plates and further incubated with N. indicum extract (0.5; 1; and 2 µg/ml) and control medium for 72 h.

**Measurement of TGF-β1 expression**

The protocol of TGF-β1 measurement was performed according to the procedure issued by Koma Biotech Inc. as the manufacturer of the human TGF-β1 with Catalog No: K0332110.

**Measurement of VEGF expressions**

The protocol of VEGF measurement was performed according to the procedure issued by Koma Biotech Inc. as the manufacturer of the human VEGF with Catalog No: K0331132.

**Statistical analysis**

All data are expressed as means ± standard deviation (SD). Differences between control and experimental groups were analyzed by one-way ANOVA followed by Bonferonni’s post-hoc test, with p < 0.05 considered as statistically significant. All calculations were performed using SPSS statistical software (IBM Corp., Chicago).

**Results**

**TGF-β1 expression**

The expressions of TGF-β1 statistically significance of N. indicum extract with various concentrations 0.5 µg/ml (9.27 ± 2.9 pg/ml), 1 µg/ml (9.26 ± 2.32 pg/ml), and 2 µg/ml (6.23 ± 2.02 pg/ml) were lower than control group (21.35 ± 5.03 pg/ml). The effect of the ethanolic extract of N. indicum on the expression of TGF-β1 in keloid fibroblasts is shown in Figure 1.

Figure 1 shows that TGF-β1 expression was significantly lower in the ethanolic extract N. indicum groups compared to those in keloid fibroblast without treatment, according to increased concentration (p < 0.05).

**VEGF expression**

The expression of VEGF supernatant treatment groups of N. indicum extract with various concentration
Ethanolic Extract of Nerium Indicum Mill. Decrease TGF-β1 and VEGF in Keloid

Discussion

Our study was able to find lower expression in TGF-β1 and VEGF levels in N. indicum Mill. extract treatment groups compared to the control medium group, which showed the antikeloid effect of N. indicum ethanol extract. A significant decrease in keloid fibroblast TGF-β1 levels occurred at all of the N. indicum extract concentrations (2 µg/ml, 1 µg/ml, and 0.5 µg/ml) compared to those in the control group (p < 0.05). This is in accordance with previous studies by Dachlan (2019) that showed 5α-oleandrin isolates from ethanol extraction of N. indicum leaves significantly decreased TGF-β1 expression compared to control medium (p < 0.05) [8]. Increased TGF-β1 activity in fibroblast cells can enlarge the ability to stimulate tissue remodeling and the excessive process of wound healing causes keloid tissue. TGF-β1 plays an important role in pathogenesis of fibrosis because of its ability to initiate and maintain activation of keloid fibroblasts. The downstream pathway of TGF-β1 signaling is activated by Smad 2/3 protein which regulates increased proliferation in fibroblast cells as well as transcription factors that can activate genes which produce cytokines and TGF-β1 [10].

Increased TGF-β1 activity in keloids can also induce transcription factor activator protein-1 (AP-1) which increases collagen type 1 production and extracellular protein synthesis [11]. In addition, there is also a 6/7 Smad protein which plays a role in Smad 2/3 activation termination (negative feedback). Protein inhibition of Smad 2/3 can suppress genes that produce TGF-β1, type I collagen synthesis, and decrease ECM deposition so that it can inhibit fibrosis [12], [13].

The active compound Oleandrin contained in N. indicum extract can inhibit activation of signal transduction such as AP-1 which is mediated through inhibition of JNK and MEK, thereby suppressing the genes that synthesize TGF-β1 growth factor [14]. There are obstacles of TGF-β1 signaling activity from the active compound Oleandrin contained in N. indicum extract which can be an indicator that supports keloid therapy. Mechanical transduction is also reported to affect cell function. On the surface of keloid tissue, there is often a higher mechanical emphasis than the surrounding tissue, and this is influenced by the expression of TGF-β1 which can regulate the expression of smooth muscle actin (SMA). TGF-β1 can increase cell rigidity through interactions between TGF-β1 receptors and SMA axis so that it can also be targeted for keloid therapy [15]. Recent research using TGF-β1 oligonucleotide can provide long-term effects in inhibiting fibrosis both in vitro and in vivo. Administration of anti-TGF-β1 antibodies in experimental animals was also reported to reduce fibrosis [16].

In this study, the VEGF-A expression of keloid fibroblasts was measured at the concentration of N. indicum 2 µg/ml and 1 µg/ml extract and showed a significantly lower VEGF-A level compared to the medium control (p < 0.05).
C isolates from plants significantly reduced VEGF-A expression in keloid fibroblast cultures compared to the control medium group (p < 0.05) [17].

Oleandrin compounds from N. indicum extract have a steroid chemical structure that can bind to glucocorticoid receptors (GR) on keloid fibroblast cells so that they can inhibit transcription factor signaling which induces genes’ expression of VEGF-A. In addition, the lactone chemical structure which is also present in Oleandrin plays a role in signaling pathway receptor tyrosine kinase (VEGFR) through inhibition of extracellular regulated kinase (ERK) proteins so that VEGFR phosphorylation does not occur [18].

VEGF-A is an active protein homodimer that plays a role in angiogenesis. Angiogenesis occurs together with fibroplasia and is interdependent. Collagen and ECM when formed must always get oxygen and nutrients so that metabolic processes can occur [19]. Some of the most important mechanisms for regulating VEGF-A are hypoxia. The hypoxic condition will induce a hypoxia-inducible factor-1alpha (HIF-1α) to bind with VEGF receptors, triggering the tyrosine kinase pathway to angiogenesis [20]. Some cytokines and other growth factors can also increase VEGF-A expression. TNF-α is an inflammatory cytokine that has a strong biological activity to increase VEGF-A. Other cytokines such as IL-1 and IL-6 can also stimulate VEGF-A. Other growth factors such as TGF-β, EGF, and PDGF-BB can also induce VEGF-A [21].

In keloid tumors, there is an increased VEGF expression that binds to the VEGFR receptor, activating signaling pathways for angiogenesis and neovascularization of tyrosine kinase. Activation of VEGFR by VEGF-A causes autophosphorylation of tyrosine residues at the VEGFR receptors, thereby activating mitogen-activated protein-kinase (MAPK) which causes cell proliferation and migration as well as activation of AKT/ERK proteins producing eNOS so that vascular permeability increases [22]. Fibrosis in keloid tissue is caused by increased VEGF-A phosphorylation with its receptors. Increased VEGF-A can occur exogenously and endogenously. Exogenous VEGF-A will increase the phosphorylation of VEGFR-A receptors, thereby increasing proliferation of keloid fibroblasts, while endogenous VEGF-A will increase the activation of transcription factors from VEGF-A and IGF gene expressions in keloid tissue fibroblasts [18], [19].

Conclusion

Based on the results of this research, it can be concluded that the ethanolic extract of N. indicum Mill. can decrease expressions of TGF-β1 and VEGF in keloid fibroblast cultures. Further research is necessary to examine the effect of N. indicum extract on Smad 2/3 and Smad 6/7 expressions, as well as the expression of AP-1 transcription factors in keloid fibroblasts to support the molecular mechanism of N. indicum extract as a keloid therapy agent.

References


